Mesothelioma Vaccine

Mesothelioma vaccines are in development for the prevention and treatment of the asbestos-related cancer. Cancer vaccines stimulate the immune system to kill cancerous cells. Clinical trials are currently testing vaccines on mesothelioma patients.

Content Contributors

Scroll

Written By

Edited By

This page features: 11 cited research articles

Vaccines are traditionally used to prevent diseases. Traditional vaccines are made from small amounts of weak or dead viruses, bacteria and toxins. They prepare your immune system to fight diseases so that you don’t get sick.

Researchers are developing vaccines to treat cancer in addition to preventing it. Cancer vaccines either prevent cancer development or treat a cancer that has already developed.

Vaccines that aim to prevent cancer are called preventative cancer vaccines. Vaccines that aim to treat cancer are a type of immunotherapy called therapeutic cancer vaccines.

Vaccination leads to immunization, which makes a person immune to developing diseases or cancers.

The U.S. Food and Drug Administration (FDA) has approved only one therapeutic cancer vaccine. Sipuleucel-T (Provenge) was approved in 2010 to treat advanced prostate cancer.

The FDA has approved a number of preventative cancer vaccines such as the HPV vaccine that prevents cervical cancer and the hepatitis B vaccine that prevents liver cancer.

No preventative or therapeutic cancer vaccine has been approved to treat mesothelioma, but researchers are working to develop them.

How Does a Cancer Vaccine Work?

Cancer vaccines stimulate the acquired immune system, also called the adaptive immune system, to get the immune system to recognize and attack cancer cells.

Cancer vaccines may prevent cancer from returning, kill cancer cells or stop cancer cells from growing and spreading.

Cancer vaccines work by targeting antigens, which are proteins on the surface of diseased cells, viruses and bacteria. Cancer vaccines help the immune system recognize antigens on cancerous cells and kill the cells.

Most cancer vaccines contain or are administered with adjuvants, which help boost the immune response. Vaccines are generally considered safe.

No vaccine for mesothelioma has proven effective yet, but clinical trials are testing new vaccines on a regular basis.

What Clinical Trials Are Testing Mesothelioma Vaccines?

Therapeutic cancer vaccines for mesothelioma are only available through clinical trials. A lot of the research on mesothelioma vaccines remain in the preliminary phases of testing in animal models.

Preventative Vaccine for Mesothelioma

Researchers at the University of Hawaii are working on a preventative mesothelioma vaccine called HIvax. It targets survivin, a protein found in mesothelioma cells.

According to a 2015 study published in Human Vaccines and Immunotherapeutics, HIvax remains in the animal testing phase and has not been tested in human clinical trials.

Find a Mesothelioma Clinical Trial

Our Patient Advocates can help you find an actively recruiting mesothelioma clinical trial near you.

Get Free help

WT1 Vaccine for Mesothelioma

A phase II clinical trial of the WT1 vaccine in mesothelioma patients reported a median overall survival of 21.4 months in participants receiving the vaccine. Those who received a placebo survived 16.6 months.

These results helped the vaccine receive orphan drug status by the FDA in 2016. The orphan drug program facilitates approval for drugs that show promise in treating rare conditions.

A phase III trial is in the works and will begin when funding becomes available.

Stem Cell Vaccine for Mesothelioma

Researchers at Stanford University School of Medicine are working on a stem cell vaccine for mesothelioma and other cancers.

The stem cell vaccine uses induced pluripotent stem (IPS) cells, which are a patient’s own cells that are modified in a lab and then injected back into the patient to stimulate an immune response.

According to a 2018 study published in the journal Cell Stem Cell, the research is still in animal models and not yet tested in humans.

CRS-207 Clinical Trial Halted

Although the CRS-207 vaccine received orphan drug status from the FDA in 2015, a phase II trial of the vaccine was stopped in 2017.

The trial was halted because the vaccine was not working well enough.

Get the Best Treatment Options

Find a Doctor
Asbestos.com Mesothelioma Packet

Order Your Free Treatment Guide

Get Yours Now

Find a Mesothelioma Clinical Trial Near You

Get Help Now

Share this article

Last Modified September 24, 2018

Registered Nurse and Patient Advocate

Karen Selby joined Asbestos.com in 2009. She is a registered nurse with a background in oncology and thoracic surgery and was the regional director of a tissue bank before becoming a Patient Advocate at The Mesothelioma Center. Karen has assisted surgeons with thoracic surgeries such as lung resections, lung transplants, pneumonectomies, pleurectomies and wedge resections. She is also a member of the Academy of Oncology Nurse & Patient Navigators.

Walter Pacheco, Managing Editor at Asbestos.com
Edited by
Reviewed by placeholder
Medical Review By

6 Cited Article Sources

  1. HHS. (2017, December). Vaccine Basics.  
    Retrieved from: https://www.vaccines.gov/basics/index.html
  2. ASCO. (2016, December). What are Cancer Vaccines?
    Retrieved from: https://www.cancer.net/navigating-cancer-care/how-cancer-treated/immunotherapy-and-vaccines/what-are-cancer-vaccines
  3. Hoffmann, P.R. et al. (2015). Preclinical development of HIvax: Human survivin highly immunogenic vaccines.
    Retrieved from: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4514257/
  4. Kooreman, N.G. et al. (2018). Autologous iPSC-Based Vaccines Elicit Anti-tumor Responses In Vivo. 30016-X
    Retrieved from: http://www.cell.com/cell-stem-cell/pdfExtended/S1934-5909(18)
  5. Sellas Life Sciences Group. (n.d.). Galinpepimut-S (GPS) Therapy.
    Retrieved from: https://www.sellaslifesciences.com/galinpepimut-s-gps-therapy/default.aspx#section=therapy
  6. Zauderer, M.G. et al. (2017). A Randomized Phase II Trial of Adjuvant Galinpepimut-S, WT-1 Analog Peptide Vaccine, after Multimodality Therapy for Patients with Malignant Pleural Mesothelioma. Retrieved from: http://clincancerres.aacrjournals.org/content/early/2017/09/28/1078-0432.CCR-17-2169
  •  
  •  
  •  

Did this article help you?

Did this article help you?

Thank you for your feedback. Would you like to speak with a Patient Advocate?

On This Page

Back to Top

On This Page

Content Contributors

Share Our Page

Free Awareness Wristbands

Get free mesothelioma wristbands to show support for a loved one

Get your wristbands Mesothelioma Wristbands
Chat live with a patient advocate now loading spinner